Overview
Background
Junxian Lim is an accomplished molecular biologist at the Institute for Molecular Bioscience. With a strong background in cell biology, protein biochemistry, and pharmacology, he has established himself in the field. Collaborating with researchers at universities, institutions, as well as international industry partners like AstraZeneca and Sosei Heptares, he has contributed significantly to advancing scientific knowledge.
Throughout his doctoral studies, Junxian authored seven ground-breaking studies focused on the development of novel bioactive inhibitors targeting immune cells and inflammatory diseases. These contributions have paved the way for innovative approaches to drug development. Utilizing his expertise, he has successfully developed and characterized a diverse range of protein and cellular assays that enable in-depth investigations into immunity and inflammation. His research findings have been published in prestigious scientific journals, including Nature Communications, Cell Reports, Journal of the American Chemical Society, Diabetes, Journal of Medicinal Chemistry, and the British Journal of Pharmacology. His work has been highly cited, reflecting its impact and significance within the scientific community.
Recognized for his outstanding mentoring abilities, Junxian has supervised or co-supervised the research of two completed PhD students, six completed MPhil students, and three completed Honours students. The success of his former students is a testament to his dedication and guidance. They continue to excel and actively contribute to research endeavours around the world, spanning countries such as Australia, Singapore, Korea, India, Japan, and China.
Beyond his research and mentoring achievements, Junxian actively participates in the scientific community. He serves on the editorial boards of esteemed journals like Journal of Translational Medicine, Frontiers in Molecular Biosciences and Biology. This involvement allows him to stay at the forefront of scientific advancements and contribute to the dissemination of knowledge within his field.
Availability
- Dr Junxian Lim is:
- Available for supervision
- Media expert
Fields of research
Qualifications
- Bachelor of Science, The University of Queensland
- Bachelor (Honours) of Science (Advanced), The University of Queensland
- Doctor of Philosophy, The University of Queensland
- Journal Editorial Board Member, Frontiers in Molecular Biosciences, Frontiers in Molecular Biosciences
- Journal Editorial Board Member, Journal of Translational Medicine, Journal of Translational Medicine
- Member, Royal Society of Biology, Royal Society of Biology
Research interests
-
Molecular and cellular mechanisms of diseases
His research focuses on the molecular and cellular mechanisms of diseases, and the development of new therapies. Some of his recent research findings include: - Identification of new therapeutic targets and the development of small molecule inhibitors to target these targets, with the goal of improving current treatments and outcomes - Investigation of the molecular mechanisms that contribute to diseases with the goal of developing novel strategies and improve treatment efficacy
-
Experimental therapeutics for inflammatory diseases and cancers
Inflammation is a normal physiological response to tissue injury, however uncontrolled inflammation leads to diseases and cancer risk or progression. My current research is focused on developing approaches to better understand the fundamental basis of key proteins involved in uncontrolled inflammation responses and tumourigenesis.
-
Protein-protein interactions
Protein-protein interactions essentially control all biological functions and are considered as the most basic mechanisms underlying many diseases. Therefore, protein-protein interactions are potential targets in drug development. By merging different approaches in chemistry, biochemistry and pharmacology, we seek to better understand and modulate protein-protein interactions involved in diseases.
Works
Search Professor Junxian Lim’s works on UQ eSpace
2013
Journal Article
C5aR and C3aR antagonists each inhibit diet-induced obesity, metabolic dysfunction, and adipocyte and macrophage signaling
Liu, Junxian, Iyer, Abishek, Suen, Jacky Y., Seow, Vernon, Reid, Robert C., Brown, Lindsay and Fairlie, David P. (2013). C5aR and C3aR antagonists each inhibit diet-induced obesity, metabolic dysfunction, and adipocyte and macrophage signaling. The FASEB Journal, 27 (2), 822-831. doi: 10.1096/fj.12-220582
2012
Journal Article
An inhibitor of phospholipase A2 group IIA modulates adipocyte signaling and protects against diet-induced metabolic syndrome in rats
Iyer, Abishek, Lim, Junxian, Poudyal, Hemant, Reid, Robert C., Suen, Jacky Y., Webster, Julie, Prins, Johannes B., Whitehead, Jonathan P., Fairlie, David P. and Brown, Lindsay (2012). An inhibitor of phospholipase A2 group IIA modulates adipocyte signaling and protects against diet-induced metabolic syndrome in rats. Diabetes, 61 (9), 2320-2329. doi: 10.2337/db11-1179
2010
Journal Article
Antifibrotic activity of an inhibitor of histone deacetylases in DOCA-salt hypertensive rats
Iyer, Abishek, Fenning, Andrew, Lim, Junxian, Le, Giang T, Reid, Robert C, Halili, Maria A, Fairlie, David P and Brown, Lindsay (2010). Antifibrotic activity of an inhibitor of histone deacetylases in DOCA-salt hypertensive rats. British Journal of Pharmacology, 159 (7), 1408-1417. doi: 10.1111/j.1476-5381.2010.00637.x
2009
Journal Article
Structure-activity relationships for substrate-based inhibitors of human complement factor B
Ruiz-Gomez, G, Lim, J, Halili, M. A., Le, G. T., Madala, P. K., Abbenante, G and Fairlie, D. P. (2009). Structure-activity relationships for substrate-based inhibitors of human complement factor B. JOURNAL OF MEDICINAL CHEMISTRY, 52 (19), 6042-6052. doi: 10.1021/jm900781m
Supervision
Availability
- Dr Junxian Lim is:
- Available for supervision
Before you email them, read our advice on how to contact a supervisor.
Available projects
-
Protein-protein interactions
Protein-protein interactions are key to the regulation of biological processes in all forms of life and in disease. Our group seeks to understand complex protein-protein interactions that have traditionally thought to be “undruggable”. Projects are avaliable to investigate novel proteins, signalling pathways and molecules using advanced imaging and microscopy, protein biochemistry, cell-based assays, peptide synthesis and NMR spectroscopy.
Projects include
- Drug design and discovery (peptide synthesis, peptidomimetics, in silico-assisted, NMR structure, dynamics)
- Drug mechanisms of action (cell biology, signalling pathways, enzymology, GPCRs)
- Pharmacology (rodent models of inflammatory diseases)
-
Therapeutics for inflammatory diseases and cancers
Our group investigates molecular mechanisms of chemical reactions, biological processes, disease development and drug action. My team seeks to understand various aspects of inflammation, from mediators and signaling pathways to therapeutic opportunities. Projects are avaliable to investigate new approaches to modulate G-protein coupled receptors (GPCRs) signalling, cell & molecular biology or pharmacology (animal models of inflammatory diseases, allergies & asthma, cancers).
Projects include
- Molecular pharmacology (ligand binding, ligand potency, receptor mutagenesis, in silico modelling and docking)
- Bioactive peptides and peptide-based drug discovery (peptide synthesis, NMR spectroscopy, microscopy and flow cytometry)
Supervision history
Current supervision
-
Doctor Philosophy
G protein-coupled Receptors in Colon and Kidney Cancer
Principal Advisor
Other advisors: Professor David Fairlie
-
Master Philosophy
Mechanisms of GPCR activation
Associate Advisor
Other advisors: Professor David Fairlie
-
Doctor Philosophy
Glucose and lipid metabolism and mechanism study of active compounds.
Associate Advisor
Other advisors: Professor David Fairlie
-
Doctor Philosophy
Developing a new type of drug for inflammatory disease
Associate Advisor
Other advisors: Professor David Fairlie
-
Doctor Philosophy
Therapeutic strategies to inhibit oncogenic transcription factors
Associate Advisor
Other advisors: Dr Tim Hill, Professor David Fairlie
Completed supervision
-
2020
Doctor Philosophy
GLP-1 Receptor Signaling By Novel GLP-1 Analogues
Associate Advisor
Other advisors: Professor David Fairlie
-
2018
Doctor Philosophy
Modulating Protease-Activated Receptor 2
Associate Advisor
Other advisors: Dr Jacky Suen, Professor David Fairlie
Media
Enquiries
Contact Dr Junxian Lim directly for media enquiries about:
- biology
- cancer
- GPCR
- in-vitro protein labeling
- inflammation
- metabolic dysfunction
- obesity
- pharmacology
- protein-protein interactions
Need help?
For help with finding experts, story ideas and media enquiries, contact our Media team: